Gerardo Hernandez has sold TMDX and made no open-market buys since Dec 2025

Gerardo Hernandez is the Chief Financial Officer and Treasurer of TransMedics Group, Inc. (TMDX), appointed effective December 2, 2024, succeeding Stephen Gordon.( At age 54, he leads the finance function at the organ transplant technology leader, focusing on operational excellence, margin improvements, and supporting high-growth initiatives.(

Hernandez brings over 25 years of finance experience in healthcare and consumer packaged goods, most recently as Vice President Finance and Head of Corporate Financial Planning & Analysis (FP&A) at Alnylam Pharmaceuticals (2020–2024), where he led global teams during rapid scaling.( Previously, he headed Corporate FP&A at Shire (2010–2019), contributing to its $62 billion acquisition by Takeda, and led FP&A integration there (2019–2020); earlier roles were at Unilever (1994–2010).( He holds a B.S. in Finance from the University of Wisconsin–La Crosse and an MBA in Strategy & Economics from Fundação Getulio Vargas in São Paulo.( In March 2026, Hernandez sold TMDX shares worth $1.12 million via SEC Form 4 filings.(

Written by Perplexity from public sources.